12 results about "Nociception" patented technology

The present disclosure provides compositions and methods for treating and preventing localized nociception, inflammation, or morphological changes associated with joint disease or illness, back or spine conditions or disorders, and musculoskeletal diseases or dysfunction.

The present invention relates to a synergistic composition for controlling headache disorders. The composition comprises Palmitoylethanolamide, Magnesium, and Ginkgolide B, along with pharmaceutically acceptable excipients. The invention addresses primary headache disorders, including migraine and tension-type headaches, which represent the majority of headache disorders. Palmitoylethanolamide exhibits analgesic and anti-inflammatory properties, down¬ regulating pro-inflammatory and nociceptive pathways. Magnesium contributes to the reduction of headache symptoms, while Ginkgolide B, derived from Ginkgo biloba, enhances the therapeutic effect. Animal studies have demonstrated the synergistic efficacy of this combination in reducing the frequency, duration, and severity of headache symptoms, both independently and when used with standard treatments.

The present invention relates to a process for production of nerve growth factor (NGF) and muteins thereof, in particular muteins of human NGF. The process of the present invention yields nerve growth factor (NGF) and muteins thereof, e.g. from recombinant sources, at high purity. Aspects related to the process of the present invention, such as muteins obtainable thereby, are also described. The respective muteins may be characterized e.g. by improved detectability and / or reduced nociceptive activity, compared to wildtype human NGF.

A hemodynamic monitoring system monitors a patient's arterial pressure and provides an alert to a medical professional of the patient's nociception. The system includes a hemodynamic sensor that generates hemodynamic data representative of the patient's arterial pressure waveform. A hardware processor of the system is configured to execute nociception detection software code to perform waveform analysis of the hemodynamic data to determine a plurality of signal measurements. Detection input features indicative of a nociceptive event in the patient are extracted by the processor from the plurality of signal measurements. A nociceptive score representative of a probability of a nociceptive event in the patient is determined from the detection input features. A sensory alarm is activated in response to the nociceptive score meeting a predetermined detection criterion.

This invention relates to the fields of medical data processing and multimodal emotion computing, and discloses an emotion state recognition system for vocal micro-expressions in patients with advanced cancer. The system constructs a temporal state vector reflecting the patient's neural control ability by calculating the neural conduction lag rate and the physiological vocal energy index. A state-adaptive gating module generates a confidence mask to weight the multimodal features. Subsequently, an emotion decoupling and reconstruction module uses manifold orthogonal projection to separate the weighted features into physiological harm perception components and psychological emotional response components, and combines sparse dictionary reconstruction to remove noise. Finally, a fusion decision and grading module combines a temporal convolutional network with an adaptive threshold calibration mechanism based on the energy index to output pain grading results and decision signals. This invention can effectively distinguish between a patient's subjective masking and physiological exhaustion state, decouple the physical and psychological attributes of pain, and avoid missed detections due to weak reactions.

The invention provides hydrochloride hydrate solid forms of the compound MCOPPB (i.e., (R)-1-(1-(1-methylcyclooctyl)piperidin-4-yl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole), pharmaceutical compositions thereof, methods for preparing the same, and their use in agonizing the NOP receptor (i.e., the nociceptin / orphanin FQ receptor) and treating a disease or condition mediated by a NOP receptor, such as pain.

Systems and methods are provided for patient monitoring and / or treatment. The system may include one or more sensors configured to measure electroencephalogram (EEG) and electrodermal signals of a patient subject to at least one anesthetic agent and at least one analgesic agent during an operative medical procedure. The system can also include a processor, operably coupled to the one or more sensors. The processor is configured to receive the EEG and electrodermal signals and, using the EEG or electrodermal signals, generate a report indicating the nociceptive state of the patient in real-time during the operative medical procedure while the patient is subject to the at least one anesthetic and a pain management plan based on desired post-operative outcomes..

Substituted cyclohexyl chemical entities of Formula (I):wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.

In some examples, a patient monitoring system includes processing circuitry configured to detect an occurrence of a nociception event of a patient during a medical procedure. The processing circuitry may, for example, determine, based at least in part on a nociception parameter of the patient in an interrogation window, a nociception parameter level, determine, based at least in part on the nociception parameter of the patient in a baseline window that corresponds to the interrogation window, a baseline nociception parameter level, determine a difference in nociception parameter levels between the baseline nociception parameter level and the nociception parameter level, detect, based at least in part on the difference in nociception parameter levels, an occurrence of a nociception event, and in response to detecting the occurrence of the nociception event, provide an indication to adjust an amount of analgesic administered to the patient.